Skip to content
July has turned out to be a good month for the fight against Alzheimer’s, with the approval of a new plaque-reducing drug and a […]
Kisunla approval and proposed CMS change signal progress against Alzheimer’s Read More »
2001 was the dawn of the modern era of biosecurity in the United States. Following the 9/11 attacks and deadly anthrax letters, the nation
The House Ways and Means Committee learned how lawmakers can enable progress in biotech from a Biotechnology Innovation Organization (BIO) Board member and the
BIO Board member and head of BioUtah testify at House field hearing Read More »
The Federal Trade Commission (FTC) released an interim report on July 9 criticizing the negative impact pharmacy benefit managers (PBMs) have on prescription drug
FTC releases interim report criticizing PBMs Read More »
A few topics keep popping up in discussions about the future of U.S. healthcare over the past couple of years. The need to pass
3 key priorities shaping the future of U.S. healthcare and biotech Read More »
A bill to reauthorize a program that encourages the development of pediatric rare disease treatments was introduced in the Senate on June 20. Bill
Pediatric Priority Review Voucher reauthorization introduced in Senate Read More »
The new SAF Coalition, which seeks to promote sustainable aviation fuel (SAF), just added 10 new members—including the Biotechnology Innovation Organization (BIO)— according to
BIO joins new SAF Coalition promoting sustainable aviation fuel Read More »
In implementing the Inflation Reduction Act (IRA), the Centers for Medicare and Medicaid Services (CMS) has made efforts to unnecessarily broaden the law with
CMS overreach will impede innovation Read More »
With rapid innovations in agriculture, energy, and environmental biotech, the industry must try to educate regulators and the public about the latest scientific advances
BIO 2024: Education can improve regulation, biotech innovators say Read More »
Biopharma supply chains, streamlining regulation, and other critical issues came up when the leader of the U.S. agency regulating drugs spoke with the leader
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health Read More »
